ESR1 and breast carcinoma: About three quarters of triple-negative breast cancers (TNBCs)—i.e., estrogen receptor (ER)-, progesterone receptor (PR)- and not overexpressing HER2[2]—express basal markers, so the triple-negative type is frequently taken as a surrogate marker of basal-like breast cancer.